FlowMetric, a Doyleston, Pa.-based provider of flow cytometry and cell sorting services, has formed a new affiliate company, FlowMetric Diagnostics, for developing advanced companion diagnostics from its flow cytometry platform for use in the global health market.

Flow cytometry currently has broad applications in R&D as well as drug design. The sensitivity and analytical capabilities of the modern flow cytometry systems combined with FlowMetric Diagnostics proprietary methods could play a central role in its development of novel and innovative diagnostics.

"This new affiliate company," said Ren Capocasale, FlowMetric CEO, "represents the natural progression of the FlowMetric business into the clinical marketplace and recognizes the need for additional diagnostics."

FlowMetric Diagnostics leadership will include Amy Williams, president, and Julie Bick, Ph.D., chief scientific officer. Capocasale is chairman of the board.

"The development of new companion diagnostics through flow cytometry can help to advance personalized medicine and better meet the needs of physicians, healthcare workers and patients," said Williams.

FlowMetric Diagnostics plans to establish a state-of-the-art FDA-compliant clinical flow cytometry laboratory in which to perform CLIA-certified diagnostic tests from both the company's own assay portfolio, as well as those of partnering diagnostic companies.